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ABSTRACT
Background. Recent studies have shown red blood cell 
distribution width (RDW) as a marker for severity and 
prognosis in coronary artery disease patients. Other 
studies have also correlated RDW with diabetes mel-
litus and inflammation. However, such correlation and 
prognosis in patients with concomitant coronary artery 
disease and diabetes after percutaneous intervention 
remains unclear. 
Material and methods. Our study group comprised 
of 730 subjects including 700 patients (cases) and 30 
normal subjects (control group). Patients who pre-
sented with coronary artery disease were divided into 
diabetic and non-diabetic groups. All patients had RDW 
measured at admission and percutaneous intervention 
was done. Follow-up for adverse events was carried 
out between 6 to 12 months. 
Results. RDW was elevated in patients as compared 
to control group (p < 0.05). RDW correlated well with 
inflammatory markers including erythrocyte sedimen-
tation rate, C-reactive protein, HbA1c, white blood 
cells and troponin. RDW was higher with more severe 
atherosclerosis based on SYNTAX and Gensini scores 
(p < 0.05). Prognosis was found to be worse in patients 
with high RDW as well as in diabetics. 
Conclusions. RDW has positive correlation with other 
inflammatory marker. It may be used as a marker in 
determining the severity and prognosis in diabetic 
patients with coronary artery disease. (Clin Diabetol 
2020; 9; 3: 174–178)
Key words: red cell distribution width, coronary 
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Introduction
Guidelines for acute ST elevation myocardial infarc-
tion (STEMI) patients recommend primary PCI as the 
preferred reperfusion strategy [1]. Inflammation plays 
a critical role in the initiation and propagation of the 
atherosclerotic process [2, 3]. Numerous inflamma-
tory markers and indices have been studied recently 
in relation to atherosclerosis. One such marker is red 
cell distribution width (RDW). Use of RDW has been es-
tablished in the investigation of the etiology of anemia 
[4]. Moreover, recent studies are showing an increasing 
evidence linking elevated RDW with adverse outcomes, 
in patients with coronary artery disease, heart failure 
(HF) and with metabolic syndrome. Diabetes mellitus 
(DM) is an independent risk factor for heart failure 
(HF) [4–6]. 
HbA1c is associated with type 2 diabetes patients 
and is a marker of long term glucose homeostasis as 
well as adequacy of glycemic control in diabetic patients 
[7]. HbA1c level increase with age, chronic subclinical 
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inflammation and possibly oxidative stress and also 
in conditions that can adversely affect red blood cell 
survival. Correlation of RDW and diabetes in coronary 
artery disease patients has not been studies well.
Therefore, the aim of this exploratory study was 
to investigate the correlation and prognostic value of 
RDW in diabetes and coronary artery disease patients.
Patients and methods
It is a retrospective clinical study which included 
patients admitted to our hospital with coronary artery 
disease and diabetes. For the purpose of this analysis 
patients were divided into low RDW, high RDW, dia-
betic and non-diabetic groups. ST elevation myocardial 
infarction (STEMI) was defined as typical chest pain last-
ing for at least 30 min with new ST-segment elevation 
at the J point in more than two contiguous precordial 
or inferior leads (> 0.2 mV in V1 through V3 and > 
0.1 mV in the other leads) [8]. Diabetes was defined 
according to definition previous stated elsewhere [9].
Hypertension was defined as repeated SBP meas-
urements at least 140 mm Hg, repeated DBP measure-
ments at least 90 mm Hg or chronic treatment with 
antihypertensive medications. Diabetes was recorded 
when it was reported by the patient and appeared in 
their medical records or if the patient was receiving 
regular treatment with oral hypoglycemic agents or 
insulin. Dyslipidemia was defined as a low-density 
lipoprotein-cholesterol level above the target according 
to National Cholesterol Educational Program-3 recom-
mendations, as a high-density lipoprotein-cholesterol 
level below 40 mg/dL, or chronic treatment with lipid-
lowering drugs prior to hospitalization [10].
All patients with an ACS received aspirin (325 mg 
loading dose) on admission and 100 mg daily as well 
as clopidogrel (300 mg loading dose for patients < 75 
years of age and 75 mg for patients > 75 years of age). 
PCI was done for all STEMI patients.
Blood samples were taken on admission from all 
patients at the time of hospitalization and prior to 
the administration of medication. All hematological 
measurements were performed using Cobas B221 and 
6000, Roche-Switzerland. Our hospital ethics commit-
tee approved this study and informed consent was 
obtained from all study participants according to the 
declaration of Helsinki.
Statistical analysis
Data was analyzed with Statistical Package for the 
Social Sciences (SPSS 20) for Windows (SPSS Inc., Chi-
cago, Illinois, USA). Continuous data are presented as 
the mean along with standard deviation. The Kolmogo-
rov-Smirnov test was used to evaluate data normality.
Independent-samples t-test was used to compare 
two groups showing normal distribution. Categorical 
variables were summarized as percentages and com-
pared with the chi-square test. Pearson’s and Spearman 
correlation analysis tests were used to determine the 
correlation between variables. P value less than 0.05 
was considered to indicate a significant difference.
Results
730 subjects were enrolled in this study which 
included 30 normal and disease free subjects and 700 
coronary artery disease patients. Mean RDW in control 
group was compared to RDW in patients which showed 
significant difference [(12.4 vs. 14.5) (p < 0.05)]. All 
patients underwent percutaneous intervention at about 
8 ± 5 hours after onset of chest pain. The patients were 
divided into groups according to RDW and diabetic 
status. The mean age of the patients was 64 ± 7.92 
years. Patients were assessed at baseline according to 
RDW levels (low and high). There was significant differ-
ence between low and high RDW groups with regard 
to hemoglobin, HbA1c, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), white blood cells (WBC) 
and troponin levels. Other demographic and clinical 
baseline characteristics between the two groups did 
not show any significant difference (Table 1). 
Angiographic characteristics and scores of the 
study groups are presented in Table 2. SYNTAX Score 
ranged from 5 to 47 and with a mean of 23.75 ± 10.12 
while Gensini Score ranged from 8 to 10 and with a 
mean of 48.31 ± 25.47. SYNTAX and Gensini score were 
divided into low and high based on mean values. RDW 
levels in relation to angiographic scoring were assessed 
in diabetics (HbA1c ≥ 7) and non-diabetics (HbA1c < 7). 
RDW levels were significantly higher with high SYNTAX 
score, Gensini scores and multi-vessel disease and as 
well as in diabetics (p < 0.05) (Table 2). 
The Pearson and Spearman correlation coefficients 
were used to assess the correlations between RDW and 
various clinical and laboratory variables. Significant 
positive correlation was found between RDW and age, 
ejection fraction, ESR, HbA1c, WBC, CRP and troponin 
while there was significant negative correlation with 
hemoglobin (p < 0.05) (Table 3).
Prognosis was assessed on the basis of five indices 
(angina, myocardial infarction, heart failure, stroke and 
death) during a period of 6 months to one year after per-
cutaneous intervention. Comparison was made between 
low and high RDW groups as well as diabetic and non-
diabetics. It showed significant increase in myocardial 
infarction, heart failure and death in both high RDW and 
diabetic groups. Moreover, frequency of angina was also 
more in diabetic group (p < 0.05) (Table 4). 
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Table 2. Relationship between RDW and angiographic 
variables in diabetic (HbA1c ≥ 7) and non-diabetic groups 
(HbA1c < 7)
Variable RDW
HbA1c < 7 HbA1c ≥ 7
SYNTAX score
Low (< 23) 12.85 ± 1.10 13.45 ± 1.7
Moderate-high (23–32) 14.24 ± 1.15 17.85 ± 1.14*
Gensini score
Low (< 47) 12.55 ± 1.18 12.55 ± 1.18
High (≥ 47) 14.37 ± 1.21 18.12 ± 1.11*
No. of vessels involved
Single vessel disease 11.97 ± 1.25 14.10 ± 1.36
Multi-vessel disease 13.78 ± 1.75 18.82 ± 1.61*
*p ≤ 0.05 
Table 1. Baseline characteristics of study groups according to RDW
Variable RDW < 16 (n = 300) RDW ≥ 16 (n = 400)
Age (years) 63 ± 7.10 65 ± 8.75
Ejection fraction (%) 50.62 ± 8.65 48.78 ± 8.10
Hypertension 99 (33%) 140 (35%)
Smoking 69 (23%) 108 (27%)
Renal failure 30 (10%) 48 (12%)
Hyperlipidemia 63 (21%) 96 (24%)
HbA1c 5.5 ± 0.5 7.5 ± 1.0*
Erythrocyte sedimentation rate [mm/h] 18 ± 5 39 ± 10*
C-reactive protein [mg/L] 0.7 ± 0.4 1.9 ± 0.6*
Troponin (high sensitivity) [ng/l] 545 ± 370 2360 ± 574*
Hemoglobin [gm/dl] 15 ± 1.0 11 ± 1.5*
White blood cells [×109/L] 9.50 ± 2.32 14.48 ± 2.25*
Aspirin 300 (100%) 400 (100%)
Clopidogrel 291 (97%) 396 (99%)
Beta blocker 285 (95%) 372 (93%)
Renin antagonists 264 (88%) 364 (91%)
Lipid lowering agents 240 (80%) 336 (84%)
*p ≤ 0.05
Table 3. Correlation of RDW with clinical and laboratory 
variables
Variable Correlation coefficient (P)
Age 0.487 (0.030)
Systolic blood pressure 0.037 (0.061)
Diastolic blood pressure 0.002 (0.346)
Ejection fraction 0.030 (0.048)
ESR 0.561 (0.001)
Serum creatinine 0.258 (0.979)
BMI 0.003 (0.0686)
Total cholesterol 0.014 (0.725)
Hemoglobin –0.486 (0.025)
HbA1c 0.529 (0.001)
WBC 0.580 (0.001)
CRP 0.349 (0.029)
Troponin 0.412 (0.017)
ESR — erythrocyte sedimentation rate; BMI — body mass indeks;  
WBC — white blood cells; CRP — C-reactive protein
Table 4. Prognosis in relation to RDW and diabetes after percutaneous intervention
RDW < 16 (n = 300) RDW ≥ 16 (n = 400) Non-diabetics (n = 380) Diabetics (n = 320)
Angina 18 (6%) 28 (7%) 20 (5.26%) 26 (8.12%)†
Myocardial infarction 4 (1.33%) 12 (3%)* 5 (1.32%) 11 (3.44%)†
Heart failure 3 (1%) 14 (3.50%)* 4 (1.05%) 13 (4.06%)†
Stroke 0 (0%) 2 (0.50%) 1 (0.26%) 1 (0.31%)
Death 3 (1%) 10 (2.50%)* 4 (1.05%) 9 (2.81%)†
*p ≤ 0.05 comparison between RDW < 16 and RDW ≥ 16 groups; †p ≤ 0.05 comparison between non-diabetic and diabetic groups
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Discussion
This study showed good correlation of RDW with 
other inflammatory markers. The underlying patho-
physiologic mechanisms for the association between 
a high RDW and atherosclerosis is unknown, but it 
is believed that inflammation might play a role with 
cytokines induced changes in the red cell membrane, 
leading to an increased RDW [11]. Erythrocyte malfor-
mation and hence increased RDW may be caused by 
oxidative stress, inflammation, and increase in choles-
terol levels in erythrocyte membrane. Inflammation or 
oxidative stress may cause increased RDW by impair-
ing iron metabolism, inhibiting the production of or 
response to erythropoietin, and shortening red blood 
cell survival [12, 13].
Lippi et al. [14] showed an increase in RDW levels 
during acute coronary syndrome and its usefulness 
for the risk stratification. Previous studies have also 
assessed the relationship between an increased RDW 
and poor reperfusion results after STEMI, increased 
risk and morbidity in hospital as well as mortality [15]. 
A possible explanation for this result is the intense 
inflammatory response in the setting of STEMI.
In our study, the RDW levels have been shown to 
be higher in patients with diabetes. A number of risk 
factors such as age, hypertension, hyperlipidemia, high 
CRP levels may play a role [12].
Fatemi et al. showed high RDW levels in patients 
with two or more vessel disease and with early phase 
of atherosclerosis [16, 17]. 
Osadnik et al. [18] demonstrated prognostic value 
of RDW in stable angina pectoris patients undergoing 
PCI by showing higher mortality in these patients with 
a high RDW level. 
RDW is a marker of inflammation and has prognos-
tic value in diabetic patients [19, 20]. The association 
between DM and RDW has been initially examined by 
Subharshree [21] showed correlation between BNP 
and RDW in diabetic patients with HF. Malandrino et 
al. [22] demonstrated the relationship between RDW 
and microvascular and macrovascular complications of 
diabetes mellitus (DM).
RDW may reflect an underlying inflammatory pro-
cess and inflammation is considered a vital component 
in the diabetic disease process as well [4, 23], which led 
to Sherif et al. [24] suggesting that RDW could be used 
as a marker of inflammation in type 2 DM.
Elevated glucose levels may affect erythrocytes in 
multiple ways such as changes in erythrocyte mem-
branes which include increased rigidity, changes in 
osmotic fragility due to changes in Na+/K+-ATPase 
activity and tubulin acetylation and increased aggrega-
tion. Other changes include defective oxygen binding 
of hemoglobin and alterations in cell as well [25–27]. 
These changes can result in increase in shear stress 
on the endothelial wall and increased blood visco- 
sity [28].
Conclusion
RDW has positive correlation with other inflamma-
tory markers. It is an inexpensive and easily accessible 
marker which can be used in determining the severi-
ty and prognosis in diabetic patients with coronary 
artery disease after percutaneous intervention. More 
pronounced inflammatory process may be responsible 
for increased severity and hence poorer prognosis in 
diabetic patients.
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